Compare · BEAT vs SYK
BEAT vs SYK
Side-by-side comparison of Heartbeam Inc. (BEAT) and Stryker Corporation (SYK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BEAT and SYK operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- SYK is the larger of the two at $122.63B, about 3952.1x BEAT ($31.0M).
- Over the past year, BEAT is down 57.2% and SYK is down 17.5% - SYK leads by 39.7 points.
- BEAT has been more active in the news (4 items in the past 4 weeks vs 3 for SYK).
- SYK has more recent analyst coverage (25 ratings vs 9 for BEAT).
- Company
- Heartbeam Inc.
- Stryker Corporation
- Price
- $0.56-3.08%
- $319.74-3.44%
- Market cap
- $31.0M
- $122.63B
- 1M return
- -24.92%
- +2.90%
- 1Y return
- -57.16%
- -17.49%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 4
- 3
- Recent ratings
- 9
- 25
Heartbeam Inc.
HeartBeam, Inc., a medical technology company, primarily focusing on telemedicine solutions that enable the detection and monitoring of cardiac disease. It focuses on providing diagnostic data to help physicians with care management of patients with cardiovascular disease. The company is developing its telehealth product that comprises a credit card sized electrocardiograms machine and a cloud-based diagnostic software system to address the rapidly growing field of remote patient monitoring. The company was incorporated in 2015 and is based in Santa Clara, California.
Stryker Corporation
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
Latest BEAT
- Maxim Group initiated coverage on HeartBeam with a new price target
- HeartBeam Awarded New U.S. Patent Expanding Acoustic Sensing and Fluid Monitoring Capabilities of Its Cable-Free ECG Device
- Heartbeam Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- HeartBeam Completes Enrollment in Heart Attack Detection Pilot Study Ahead of Schedule
- SEC Form DEFA14A filed by Heartbeam Inc.
- Heartbeam Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits
- HeartBeam Announces Strategic Shift to Accelerate Global Adoption of its Ambulatory ECG Signal Platform and Leadership Transition
- Heartbeam Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- SEC Form DEF 14A filed by Heartbeam Inc.
- SEC Form PRE 14A filed by Heartbeam Inc.
Latest SYK
- Stryker expands Mako robotics portfolio with full market release of Mako RPS
- BMO Capital Markets initiated coverage on Stryker with a new price target
- Stryker to announce second quarter 2026 financial results
- Stryker Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Stryker partners with professional golfer Shane Lowry to spotlight the caregiver journey in joint replacement
- Fresh Off Its Nasdaq Debut, a Regenerative-Medicine Upstart Is Stacking Its Board With Big-Pharma Firepower
- President and COO Stiles Spencer S gifted 1,607 shares, decreasing direct ownership by 2% to 76,027 units (SEC Form 4)
- Stryker launches TPX HD® power tool, supporting demanding orthopaedic procedures
- VP, Chief Legal Officer Fletcher Robert S sold $1,394,409 worth of shares (4,544 units at $306.87) as part of a pre-agreed trading plan, decreasing direct ownership by 30% to 10,582 units (SEC Form 4)
- Director Stryker Ronda E sold $96,792,669 worth of shares (310,000 units at $312.23) (SEC Form 4)